title: Anti-tumor and anti-osteolysis effects of the metronomic use of zoledronic acid in primary and metastatic breast cancer mouse models.
abstract: This study aims to determine the effect of metronomic (0.0125 mg/kg twice a week for 4 weeks) zoledronic acid (ZOL) on cancer propagation and osteolysis against both metastatic and primary breast cancer in mice model. From our results, metronomic ZOL resulted in a significant reduction of tumor burden and did not promote lung or liver metastasis. The metronomic ZOL appeared to be more effective than the conventional regimen (0.1 mg/kg once in 4 weeks) in reducing breast cancer tumor burden, and regulating its movement to lung and liver. This dosing schedule of ZOL showed great potential against metastatic breast cancer.
authors.affiliation: Institute of Chinese Medicine, The Chinese University of Hong Kong, Shatin, New Territories, Hong Kong.
authors.forename: Ke-Wang
authors.initials: KW
authors.lastname: Luo
authors.forename: Chun-Hay
authors.initials: CH
authors.lastname: Ko
authors.forename: Grace G L
authors.initials: GG
authors.lastname: Yue
authors.forename: Michelle Y Y
authors.initials: MY
authors.lastname: Lee
authors.forename: Wing-Sum
authors.initials: WS
authors.lastname: Siu
authors.forename: Julia K M
authors.initials: JK
authors.lastname: Lee
authors.forename: Wai-Ting
authors.initials: WT
authors.lastname: Shum
authors.forename: Kwok-Pui
authors.initials: KP
authors.lastname: Fung
authors.forename: Ping-Chung
authors.initials: PC
authors.lastname: Leung
authors.forename: Gang
authors.initials: G
authors.lastname: Li
authors.forename: Andreas
authors.initials: A
authors.lastname: Evdokiou
authors.forename: Clara B S
authors.initials: CB
authors.lastname: Lau
mesh_terms: D059250:Administration, Metronomic; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D050071:Bone Density Conservation Agents / Q000008:administration & dosage*; D001842:Bone and Bones / Q000000981:diagnostic imaging / Q000473:pathology; D004164:Diphosphonates / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D008325:Mammary Neoplasms, Experimental / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology*; D051379:Mice; D009362:Neoplasm Metastasis; D010014:Osteolysis / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D011859:Radiography; D047368:Tumor Burden / Q000187:drug effects; D000077211:Zoledronic Acid
chemical_list: D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid
keywords: Anti-osteolysis; Conventional; Metastasis; Metronomic; Zoledronic acid